BB Biotech AG logo

BION - BB Biotech AG Share Price

CHF69.35 0.2  0.3%

Last Trade - 14/08/20

Sector
Healthcare
Size
Large Cap
Market Cap £3.22bn
Enterprise Value £170.9m
Revenue £811.4m
Position in Universe 205th / 1031
Bullish
Bearish
Unlock BION Revenue
Momentum
Relative Strength (%)
1m +1.01%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -3.96%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1,499 697.9 9.50 730 5.78 728.2 155.3 0.33 -13.5%
+58.6 -55.0 -53.8 -47.1
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, BB BIOTECH AG revenues increased from SF208.8M to SF444.8M. Net income decreased 24% to SF421.7M. Revenues reflect Unrealized Gains/Losses on Securities increase from SF121.8M to SF377.1M, Foreign exchange gains net increase from -SF138K to SF38K. Net income was offset by Management Remuneration increase of 12% to SF580K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BION
Graphical History

Revenue

BION Revenue Unlock BION Revenue

Net Income

BION Net Income Unlock BION Revenue

Normalised EPS

BION Normalised EPS Unlock BION Revenue

PE Ratio Range

BION PE Ratio Range Unlock BION Revenue

Dividend Yield Range

BION Dividend Yield Range Unlock BION Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BION EPS Forecasts Unlock BION Revenue
Profile Summary

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated November 10, 1993
Public Since November 8, 2006
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange SIX Swiss Exchange
Shares in Issue 55,400,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BION Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BION
Upcoming Events for BION
Friday 23rd October, 2020
Q3 2020 BB Biotech AG Earnings Release
Frequently Asked Questions for BB Biotech AG
What is the BB Biotech AG share price?

As of 14/08/20, shares in BB Biotech AG are trading at CHF69.35, giving the company a market capitalisation of £3.22bn. This share price information is delayed by 15 minutes.

How has the BB Biotech AG share price performed this year?

Shares in BB Biotech AG are currently trading at CHF69.35 and the price has moved by 15.06% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BB Biotech AG price has moved by 14.54% over the past year.

What are the analyst and broker recommendations for BB Biotech AG?

Of the analysts with advisory recommendations for BB Biotech AG, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BB Biotech AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will BB Biotech AG next release its financial results?

BB Biotech AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the BB Biotech AG dividend yield?

The BB Biotech AG dividend yield is 4.92% based on the trailing twelve month period.

Does BB Biotech AG pay a dividend?

Last year, BB Biotech AG paid a total dividend of 3.4, and it currently has a trailing dividend yield of 4.92%. Looking ahead, BB Biotech AG has not announced an ex-dividend date yet.

When does BB Biotech AG next pay dividends?

BB Biotech AG has yet to annouce their ex-dividend date. The historic dividend yield on BB Biotech AG shares is currently 4.92%.

How do I buy BB Biotech AG shares?

To buy shares in BB Biotech AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BB Biotech AG?

Shares in BB Biotech AG are currently trading at CHF69.35, giving the company a market capitalisation of £3.22bn.

Where are BB Biotech AG shares listed? Where are BB Biotech AG shares listed?

Here are the trading details for BB Biotech AG:

Country of listing: Switzerland
Exchange: SWX
Ticker Symbol: BION
What kind of share is BB Biotech AG?

Based on an overall assessment of its quality, value and momentum, BB Biotech AG is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BB Biotech AG share price forecast 2020?

Shares in BB Biotech AG are currently priced at CHF69.35. At that level they are trading at 1.79% premium to the analyst consensus target price of 0.00.

Analysts covering BB Biotech AG currently have a consensus Earnings Per Share (EPS) forecast of 5.65 for the next financial year.

How can I tell whether the BB Biotech AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BB Biotech AG. Over the past six months, the relative strength of its shares against the market has been 22.18%. At the current price of CHF69.35, shares in BB Biotech AG are trading at 7.23% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BB Biotech AG PE Ratio?

The BB Biotech AG PE ratio based on its reported earnings over the past 12 months is 7.04. The shares are currently trading at CHF69.35.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of BB Biotech AG?

BB Biotech AG's management team is headed by:

Clive Meanwell - VCH
Daniel Koller - OTH
Felicia Flanigan - OTH
Jan Bootsma - OTH
Erich Hunziker - CHM
Silvia Siegfried-Schanz - DIR
Klaus Strein - DRC
Stephen Taubenfeld - OTH
Christian Koch - OTH
Maria-Grazia Iten-Alderuccio - DIR
Michael Hutter - CFO
Tanja Chicherio - DMK
Rudy Le Blanc - CEX
Claude Mikkelsen - DIR
Maurizio Bernasconi - OTH
Thomas von Planta - DRC
Susan Galbraith - DRC
Who are the major shareholders of BB Biotech AG?

Here are the top five shareholders of BB Biotech AG based on the size of their shareholding:

Hunziker (Erich) Individual Investor
Percentage owned: 2.63% (1.46m shares)
UBS Asset Management (Switzerland) Investment Advisor
Percentage owned: 1.43% (791k shares)
Credit Suisse Asset Management Investment Advisor/Hedge Fund
Percentage owned: 1.22% (673k shares)
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund
Percentage owned: 1.17% (648k shares)
Zürcher Kantonalbank (Asset Management) Bank and Trust
Percentage owned: 0.8% (443k shares)
Similar to BION
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.